Company Profile

Tiltan Pharma Is A Clinical Stage Biotechnology Company Focused On The Development Of Novel And Synergistic Combinations Of Known Drugs For The Treatment Of Cancerthe Company Has Pioneered A Transformational Therapeutic Approach Based On A Multi Faceted Intervention Through The Combination Of Agents That Target Differentnon Overlapping Mechanisms Of Actionthe Company S Strategy Of Targeting Approved Drugs Whendeveloping Its Drug Combinations Enjoys A Fast Regulatory Pathway On The One Hand And Strong Patent Protection Due To The Novelty Of The Combinationsproprietary Formulations And Treatment Regimenson The Otherthe Company S Leading Producttl 118Is An Orally Administereddrug Combination Of Four Generic Drugs With Anti Angiogenic And Immune Modulation Propertiestl 118 Novelty Is In Combining And Re Purposing Drugs With Complementary Mechanisms Of Actions That Are Administered In A Unique Treatment Regimendose And Scheduling The Regimen Consists Of Low Dose High Frequency Administration Of An Alkylating Agent And 3 Non Cytotoxic Agents Previously Approved For Human Usefor Non Oncological Indications Tl 118 Has Demonstrated Its Safetyefficacy And Broad Applicability In Treatment Of Some 200 Patients Suffering From A Variety Of Tumorseither As Part Of Compassionate Use Programs Or In Clinical Trials Settingfavorable Response To Treatment With Tl 118 Was Observed In Patients Suffering From Pancreaticprostateovarianbreastrccand Colorectal Cancers As Well As From Sarcomasthe Company Is Successfully Concluding A Phase 2 Clinical Trial Evaluating The Safety And Efficacy Of Tl 118 In Combination With Standard Of Caregemcitabineas Treatment For Metastatic Pancreatic Cancer Versus Gemcitabine Alonethe Study Is Conducted In Israel And In Serbia Under An Ind Application With The Results Of The Primary End Pointdisease Control Rate Measured At 16 Weeksexpected By November2016